Oramed Pharma announces publication of oral insulin.
The article presents the results of a trial that assessed the safety and efficacy of Oramed’s lead drug candidate ORMD-0801 in type 2 diabetes (T2DM). The trial met its primary endpoint and found that in patients with T2DM, bedtime ORMD-0801 curbed increases in night-time glycemia, 24-hour glycemia, and HbA1c without increasing the risk of hypoglycemia or safety events as compared to the control arm.
See-"Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes mellitus - A randomized placebo-controlled trial"-Roy Eldor MD, PhD, Joel Neutel MD, Kenneth Homer MS, Miriam Kidron PhD First published: 26 July 2021 https://doi.org/10.1111/dom.14499. Diabetes, Obesity and Metabolism.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins